Company intelligence / Profile preview

JaxBio

Ownership: Private
Development stage: Preclinical

Overview

JaxBio has developed a unique liquid biopsy blood test that uses an array-based platform combined with machine learning algorithms to detect thousands of cancer-specific biomarkers. The goal is fast, sensitive, low-cost early diagnosis and monitoring of various cancers. The company has raised over $15M in grants and investments since its founding in 2022. No published clinical results or regulatory approvals are available yet.

Therapeutic areas: Oncology
Modalities: Diagnostic test (liquid biopsy)Machine learning-based biomarker analysis
Industry: Molecular Diagnostics

Partnerships

Horizon EuropeEuropean Research CouncilRamot at Tel Aviv University

Beyond the preview

Go deeper on JaxBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JaxBio.

Explore the full profile